What is epithelioid haemangioendothelioma?
Epithelioid haemangioendothelioma (EHE) is a very rare cancer that starts in the cells lining blood vessels (endothelial cells). It is a type of vascular sarcoma, a cancer of the body’s connective tissues.
EHE most often grows in the liver, the lungs, bone and soft tissues. In many people, it is found in more than one place at the time of diagnosis, most commonly in both the liver and the lungs.
EHE is unusual because its behaviour varies a lot from person to person. In some people it grows very slowly and may stay stable for many years without treatment. In others it behaves more aggressively and spreads (Stacchiotti et al., 2021).
The World Health Organization classifies EHE as a malignant tumour (Sbaraglia, Bellan and Dei Tos, 2021). It is so rare that it affects only around 1 person in a million each year, so care is best organised through specialist sarcoma centres.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Rare vascular sarcoma of blood vessel lining cells |
| How common | About 1 in a million people a year |
| Typical age | Usually adults aged 30-50; can occur in children and older people |
| Main sites | Liver, lungs, bone and soft tissue; often several at once |
| Key symptoms | Often none; pain in the upper abdomen, chest pain, cough, tiredness |
| Gene changes | WWTR1::CAMTA1 fusion in about 90%; YAP1::TFE3 in most of the rest |
| Main treatment | Surgery, liver transplant, active surveillance, sirolimus and other drug treatments |
| Outlook | Highly variable; many people live for years, but aggressive forms occur |
2. Types of EHE
By site
| Site | Notes |
|---|---|
| Liver | The most common site; usually many nodules in both halves of the liver |
| Lung | Often many small nodules in both lungs; may cause fluid around the lungs |
| Bone | Single or several bone lesions; may cause pain or fractures |
| Soft tissue | A lump in a limb or the trunk, often linked with a blood vessel |
| Other sites | Lymph nodes, skin, heart, brain coverings and others, rarely |
By genetic type
| Genetic type | Notes |
|---|---|
| WWTR1::CAMTA1 (TAZ::CAMTA1) | Found in about 90% of EHE; the classic form (Errani et al., 2011) |
| YAP1::TFE3 | About 5-10%; often younger patients; looks slightly different under the microscope (Antonescu et al., 2013) |
| Other rare fusions | Being studied |
3. Causes and risk factors
The cause of EHE is not known. It develops when two genes break and join together inside a cell, creating a fusion gene. This fusion switches on growth programmes in the blood vessel cell.
The fusion gene arises by chance during a person’s life. It is not inherited and cannot be passed on to children.
| Question | Answer |
|---|---|
| Is EHE linked with lifestyle? | No lifestyle cause has been found |
| Is it linked with alcohol or liver disease? | No; liver EHE usually occurs in a healthy liver |
| Is it more common in women? | Liver EHE is somewhat more common in women |
| Is it contagious? | No |
4. How does it look
On scans of the liver
| Feature | Description |
|---|---|
| Number | Usually many nodules in both halves of the liver |
| Position | Often near the surface of the liver |
| Growth pattern | Nodules may join together into larger areas |
| Capsular retraction | The liver surface may pull inwards over a nodule, a typical clue |
| Target appearance | Rings of different density on CT or MRI |
| “Lollipop sign” | A nodule with a blood vessel ending at its edge on scans |
On scans of the lungs
The lungs usually show many small nodules on both sides. Some people have thickening of the lining of the lungs or a pleural effusion (fluid around the lungs), which is linked with a more aggressive course (Lau et al., 2011).
Bone and soft tissue
In bone, EHE often appears as areas of bone loss with clear edges, sometimes in several bones. In soft tissue it forms a firm lump, sometimes attached to a vein.
Under the microscope
| Feature | Description |
|---|---|
| Cell shape | Rounded “epithelioid” cells with pink cytoplasm |
| Arrangement | Cords and strands of cells in a pale, gel-like background |
| Vacuoles | Small holes inside cells, sometimes containing red blood cells; a sign of early blood vessel formation |
| Markers | Positive for CD31, CD34 and ERG, which are blood vessel markers |
| Fusion markers | Nuclear CAMTA1 staining, or TFE3 staining in the YAP1::TFE3 type |
Visible signs
Most people with EHE look well. Visible signs are uncommon, but a lump may be felt in soft-tissue EHE, and widespread liver disease can rarely cause yellowing of the skin (jaundice) or a swollen abdomen.
5. Symptoms
Many people have no symptoms, and EHE is found by chance on a scan done for another reason.
Liver EHE
- Pain or discomfort under the ribs on the right side
- Tiredness and weakness
- Loss of appetite and weight loss
- Swelling of the abdomen in advanced disease
- Jaundice, rarely
Lung EHE
- Cough, sometimes with blood
- Chest pain, especially when breathing in
- Breathlessness, particularly if fluid builds up around the lungs
Bone and soft-tissue EHE
- Bone pain, often worse at night
- A fracture after a minor injury
- A lump that may be painful
- Swelling of a limb if a vein is involved
General symptoms
| Symptom | Notes |
|---|---|
| Fatigue | Common and can be severe |
| Fever and night sweats | In some people |
| Weight loss | More common in active disease |
| Pain | Depends on site; may need specialist pain care |
When to seek medical advice
See a doctor if you have ongoing abdominal pain, cough, chest pain or a new lump.
Seek prompt help for worsening breathlessness, coughing up blood or yellowing of the skin.
6. Diagnosis
| Test | Purpose |
|---|---|
| CT of the chest, abdomen and pelvis | Shows the size and number of lesions |
| MRI of the liver | Gives a detailed view of liver nodules |
| PET-CT | Shows active areas and helps with staging |
| Biopsy | Essential to confirm the diagnosis |
| Immunohistochemistry | Confirms blood vessel markers and CAMTA1 or TFE3 |
| Molecular testing | Confirms the fusion gene |
| Blood tests | Liver and kidney function and general health |
| Echocardiogram | If fluid around the heart is suspected |
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Metastatic cancer | Comes from a cancer elsewhere; different markers |
| Angiosarcoma | A more aggressive vascular sarcoma without the EHE fusion |
| Epithelioid haemangioma | A benign vascular tumour |
| Cholangiocarcinoma | A bile duct cancer with different markers |
7. Treatment
EHE should be managed by a specialist sarcoma team. An international expert consensus guides care (Stacchiotti et al., 2021).
Active surveillance
Because EHE can be stable for long periods, many people with disease in several organs but no symptoms are offered active surveillance. This means regular scans every few months, with treatment started only if the disease grows or causes symptoms.
Local treatments
| Treatment | When it is used |
|---|---|
| Surgery | For EHE in one place or a few places that can be safely removed |
| Liver transplantation | For selected people with liver-only disease that cannot be removed (Mehrabi et al., 2006) |
| Radiotherapy | For bone or soft-tissue lesions, or to control pain |
| Ablation or embolisation | Sometimes for liver nodules |
Drug treatment
| Drug | Notes |
|---|---|
| Sirolimus | An mTOR inhibitor and a common first-line drug for progressing disease; can stabilise EHE for long periods (Stacchiotti et al., 2023) |
| Chemotherapy | Paclitaxel or anthracycline-based treatment, mainly for aggressive disease |
| Anti-angiogenic drugs | Such as pazopanib, in some people |
| Trametinib and other targeted drugs | Studied in clinical trials |
| Interferon | Used in some centres in the past |
Supportive care
| Problem | Help available |
|---|---|
| Pleural effusion | Draining the fluid, sometimes a long-term drain |
| Pain | Pain relief medicines and specialist pain teams |
| Fatigue | Pacing, exercise, treatment of anaemia |
| Emotional strain | Counselling and patient support groups |
Liver transplantation in more detail
For people whose EHE is limited to the liver but cannot be removed with surgery, a liver transplant can offer long-term control. Results are much better than for most other cancers treated in this way, and many people remain well for years after transplant.
Transplant teams usually check carefully for disease outside the liver before listing a person, because spread elsewhere lowers the benefit. A small amount of stable lung disease does not always rule out a transplant, but this is decided case by case. After transplant, people take anti-rejection medicines for life; some centres choose sirolimus-based anti-rejection treatment because it may also slow EHE.
EHE in children and young people
EHE is very rare in children. When it does occur, it may involve the liver, lungs or soft tissue and can behave more aggressively, with fluid around the lungs in some cases. Children are treated in paediatric sarcoma centres, often using the same principles as in adults: surveillance for stable disease and surgery, sirolimus or chemotherapy for progressive disease.
8. Outlook (prognosis)
The outlook for EHE is very variable. Many people live for many years, even with disease in several organs. A smaller group has aggressive disease that progresses quickly.
| Factor | Effect on outlook |
|---|---|
| Disease in one place, fully removed | Usually good |
| Stable multifocal disease without symptoms | Often good for years |
| Pleural or pericardial effusion | Poorer outlook (Lau et al., 2011) |
| Lymph node spread | Poorer outlook |
| Symptoms such as pain, weight loss or anaemia | Poorer outlook |
| Larger tumours with more dividing cells | Poorer outlook (Rosenbaum et al., 2020) |
Doctors use these factors to decide when treatment is needed and how often scans should be done.
9. Follow-up
| Situation | Follow-up |
|---|---|
| After surgery | Scans every 3-6 months at first, then less often |
| Active surveillance | Scans every 3-6 months, adjusted to how stable the disease is |
| On sirolimus | Regular scans and blood tests for side effects |
10. Living with EHE
- Find a sarcoma specialist with experience of EHE
- Connect with patient groups, such as the EHE Rare Cancer Charity and the EHE Foundation
- Keep a symptom diary, noting pain, breathlessness and tiredness
- Ask about clinical trials and registries
- Stay active as much as possible
- Ask for psychological support, as living with an uncertain, slow-moving cancer can be stressful
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is EHE a cancer? | Yes. It is a rare sarcoma, although it often grows slowly |
| Do I need treatment straight away? | Not always. Stable disease without symptoms is often watched with scans |
| Is EHE inherited? | No |
| Can EHE be cured? | It can be cured when it is in one place and fully removed; in other cases it can often be controlled for years |
| Why is it in my liver and lungs at the same time? | EHE often appears in several places at diagnosis |
| Can children get EHE? | Yes, but rarely |
| Will I need lifelong scans? | Usually yes, because EHE can change slowly over many years; scans become less frequent when the disease is stable |
| Can I have children after EHE treatment? | Many people can; discuss timing and any medicines, such as sirolimus, with your team before trying for a baby |
Research and the future
Because the fusion genes that drive EHE are known, researchers are developing drugs that target the TAZ-CAMTA1 and YAP1-TFE3 signalling pathways. International registries and patient-led research networks have helped to gather data on this rare cancer, and patients are encouraged to take part in them.
12. Questions to ask your care team
- Where exactly is my EHE, and how many lesions are there?
- Which fusion gene does my tumour have?
- Is active surveillance suitable for me?
- Could surgery or a liver transplant be an option?
- When would you recommend starting sirolimus or another drug?
- What signs should make me contact you sooner?
- Are there clinical trials or registries I can join?
Resources
- Antonescu, C.R. et al. (2013) ‘Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma’, Genes, Chromosomes and Cancer, 52(8), pp. 775-784.
- Errani, C. et al. (2011) ‘A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites’, Genes, Chromosomes and Cancer, 50(8), pp. 644-653.
- Lau, K. et al. (2011) ‘Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer’, Chest, 140(5), pp. 1312-1318.
- Mehrabi, A. et al. (2006) ‘Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy’, Cancer, 107(9), pp. 2108-2121.
- Rosenbaum, E. et al. (2020) ‘Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets’, Modern Pathology, 33(4), pp. 591-602.
- Sardaro, A. et al. (2014) ‘Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor’, Oncology Reviews, 8(2), p. 259.
- Sbaraglia, M., Bellan, E. and Dei Tos, A.P. (2021) ‘The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives’, Pathologica, 113(2), pp. 70-84.
- Stacchiotti, S. et al. (2021) ‘Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts’, ESMO Open, 6(3), 100170.
- Stacchiotti, S. et al. (2023) ‘New molecular insights, and the role of systemic therapies and collaboration for treatment of epithelioid hemangioendothelioma (EHE)’, Current Treatment Options in Oncology, 24(6), pp. 667-679.
- National Cancer Institute (2026) Epithelioid Hemangioendothelioma. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-vascular-tumors/epithelioid-hemangioendothelioma (Accessed: October 2026).
Prepared by the editorial team, October 2026.